Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Display session 1

1912 - A prospective correlative trial of personalized patient-derived xenograft (PDX) as avatars for drug therapy in patients with metastatic or recurrent soft tissue sarcomas (STS).


28 Sep 2019


Poster Display session 1


Tumour Site

Soft Tissue Sarcomas


Kanan Alshammari


Annals of Oncology (2019) 30 (suppl_5): v683-v709. 10.1093/annonc/mdz283


K. Alshammari1, E.M. Al-ezzi1, J. Lewin1, S. Salah1, Z.W.N. Veitch1, E. Malone1, G. Paris2, M. Mancini2, A. Zer1, M. Ahmad3, R. Beercroft4, A.R.R. Albiruni1

Author affiliations

  • 1 Medical Oncology, Princess Margaret Cancer Center, M5G 2M9 - Toronto/CA
  • 2 Oncology, Champions Oncology, rockville/US
  • 3 Toronto Sarcoma Program, Mount Sinai Hospital, m5g 1x5 - Toronto/CA
  • 4 Radiology, Princess Margaret Cancer Center, m5g 2m9 - Toronto/CA


Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 1912


The overall benefit from systemic treatments in advanced STS remains modest despite advances in cancer therapies. PDX models may help as avatars in guiding individualized drug use decisions.


In this prospective single center trial, fresh tumors from patients (pts) with suspected or recently diagnosed STS were engrafted into immunodeficient mice avatars (TumorGraft; Champions Oncology) and tested against a number of standard or non-licensed agents. PDX drug sensitivity profiles were then compared with real-life treatment outcomes.


Of 18 patients enrolled, 3 patients were excluded (consent withdrawal/non-sarcomas). Patient baseline characteristics are summarized in the table. Rate of engraftment was 40% (6/15 pts), while the median time from biopsy to availability of drug sensitivity profile was 379 days (186 – 421). In patients with available drug sensitivity profile (9 different drugs involving 6 pts), the mouse avatar correctly predicted the drug efficacy or lack thereof of drugs in 7 of 9 drug selection time-points (78%) and in 5 of 6 patients (83%).Table:

1718P Patient baseline characteristics

ItemEligible patients (n = 15)Engrafted patients (n = 6)
Median age (range)57 (23-76)57 (45-69)
Gender (M:F)8:73:3
Subtype - Liposarcoma - Leiomyosarcoma -UPS -Others5 3 1 62 2 1 1


PDX avatars can accurately predict drug response in STS pts. The rate of engraftment and time taken to produce drug sensitivity profiles are limitations for using this platform in guiding treatment for individual patients in real time. Nonetheless, the high degree of clinical predictability of this PDX platform may offer therapeutic value for personalized oncology approaches.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

Albiruni Razak.


Mount Sinai Sarcoma Foundation.


G. Paris: Full / Part-time employment: champions oncology. M. Mancini: Travel / Accommodation / Expenses, Shareholder / Stockholder / Stock options, Full / Part-time employment: Champions Oncology. A.R.R. Albiruni: Honoraria (self), Advisory / Consultancy, Research grant / Funding (self): Boehringer Ingelheim; Advisory / Consultancy, Research grant / Funding (self): Lilly; Advisory / Consultancy, Research grant / Funding (self): Merck; Research grant / Funding (self): CASI Pharmaceuticals; Research grant / Funding (self): Novartis; Research grant / Funding (self): Deciphera; Research grant / Funding (self): Kayopharm Therapeutics; Research grant / Funding (self): Pfizer; Research grant / Funding (self): Roche/ Genentech; Research grant / Funding (self): Boston Biomedical; Research grant / Funding (self): Bristol-Myers Squibb; Research grant / Funding (self): MedImmune; Research grant / Funding (self): Amgen; Research grant / Funding (self): GlaxoSmithKline; Research grant / Funding (self): Blueprint Medicines; Research grant / Funding (self): AbbVie; Research grant / Funding (self): Adaptimmune. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.